Literature DB >> 12543648

Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000-2001.

Ralf René Reinert1, Rudolf Lütticken, André Bryskier, Adnan Al-Lahham.   

Abstract

In a nationwide study in Germany covering 13 clinical microbiology laboratories, a total of 307 Streptococcus pyogenes (mainly pharyngitis) and 333 Streptococcus pneumoniae (respiratory tract infections) strains were collected from outpatients less than 16 years of age. The MICs of penicillin G, amoxicillin, cefotaxime, erythromycin A, clindamycin, levofloxacin, and telithromycin were determined by the microdilution method. In S. pyogenes isolates, resistance rates were as follows: penicillin, 0%; erythromycin A, 13.7%; and levofloxacin, 0%. Telithromycin showed good activity against S. pyogenes isolates (MIC(90) = 0.25 micro g/ml; MIC range, 0.016 to 16 micro g/ml). Three strains were found to be telithromycin-resistant (MIC >/= 4 micro g/ml). Erythromycin-resistant strains were characterized for the underlying resistance genotype, with 40.5% having the efflux type mef(A), 38.1% having the erm(A), and 9.5% having the erm(B) genotypes. emm typing of macrolide-resistant S. pyogenes isolates showed emm types 4 (45.2%), 77 (26.2%), and 12 (11.9%) to be predominant. In S. pneumoniae, resistance rates were as follows: penicillin intermediate, 7.5%; penicillin resistant, 0%; erythromycin A, 17.4%; and levofloxacin, 0%. Telithromycin was highly active against pneumococcal isolates (MIC(90) </= 0.016 micro g/ml; range, 0.016 to 0.5 micro g/ml). The overall resistance profile of streptococcal respiratory tract isolates is still favorable, but macrolide resistance is of growing concern in Germany.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12543648      PMCID: PMC151724          DOI: 10.1128/AAC.47.2.489-493.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Mechanisms of macrolide resistance in clinical pneumococcal isolates in France.

Authors:  F Fitoussi; C Doit; P Geslin; N Brahimi; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae.

Authors:  F Depardieu; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

3.  Multilocus sequence typing of Streptococcus pyogenes and the relationships between emm type and clone.

Authors:  M C Enright; B G Spratt; A Kalia; J H Cross; D E Bessen
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

4.  Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients with respiratory tract infections in Germany from 1998 to 1999: results of a national surveillance study.

Authors:  R R Reinert; S Simic; A Al-Lahham; S Reinert; M Lemperle; R Lütticken
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

5.  Short-course antibiotic treatment of 4782 culture-proven cases of group A streptococcal tonsillopharyngitis and incidence of poststreptococcal sequelae.

Authors:  D Adam; H Scholz; M Helmerking
Journal:  J Infect Dis       Date:  2000-07-28       Impact factor: 5.226

6.  Macrolide resistance in Streptococcus pyogenes isolates from throat infections in the region of Aachen, Germany.

Authors:  C M Brandt; M Honscha; N D Truong; R Holland; B Hövener; A Bryskier; R Lütticken; R R Reinert
Journal:  Microb Drug Resist       Date:  2001       Impact factor: 3.431

7.  Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides.

Authors:  D J Hoban; A K Wierzbowski; K Nichol; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

8.  Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage.

Authors:  A Tait-Kamradt; T Davies; M Cronan; M R Jacobs; P C Appelbaum; J Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

9.  In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species.

Authors:  J Jalava; J Kataja; H Seppälä; P Huovinen
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

10.  In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors.

Authors:  P Bemer-Melchior; M E Juvin; S Tassin; A Bryskier; G C Schito; H B Drugeon
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

View more
  24 in total

1.  Phenotypic and molecular characterization of erythromycin resistance in four isolates of Streptococcus-like gram-positive cocci causing bacteremia.

Authors:  Patrick C Y Woo; Amanda P C To; Susanna K P Lau; Ami M Y Fung; Kwok-Yung Yuen
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

2.  Association between resistance to erythromycin and the presence of the fibronectin binding protein F1 gene, prtF1, in Streptococcus pyogenes isolates from German pediatric patients.

Authors:  Maria Haller; Kirsten Fluegge; Sandra Jasminder Arri; Brit Adams; Reinhard Berner
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

3.  Resistance to erythromycin and telithromycin in Streptococcus pyogenes isolates obtained between 1999 and 2002 from Greek children with tonsillopharyngitis: phenotypic and genotypic analysis.

Authors:  Ioanna N Grivea; Adnan Al-Lahham; George D Katopodis; George A Syrogiannopoulos; Ralf René Reinert
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  Antibiotic resistance patterns among respiratory pathogens at a German university children's hospital over a period of 10 years.

Authors:  Sandra J Arri; Kirsten Fluegge; Urban Mueller; Reinhard Berner
Journal:  Eur J Pediatr       Date:  2005-08-25       Impact factor: 3.183

Review 5.  The use of macrolides in treatment of upper respiratory tract infections.

Authors:  Aleksandra K Wierzbowski; Daryl J Hoban; Tamiko Hisanaga; Mel DeCorby; George G Zhanel
Journal:  Curr Allergy Asthma Rep       Date:  2006-03       Impact factor: 4.806

6.  Identification of group A streptococcal emm types commonly associated with invasive infections and antimicrobial resistance by the use of multiplex PCR and high-resolution melting analysis.

Authors:  P Bidet; S Liguori; C Plainvert; S Bonacorsi; C Courroux; C d'Humières; C Poyart; A Efstratiou; E Bingen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-20       Impact factor: 3.267

7.  Molecular epidemiology of macrolide-resistant Streptococcus pneumoniae isolates in Europe.

Authors:  Ralf René Reinert; Adrian Ringelstein; Mark van der Linden; Murat Yücel Cil; Adnan Al-Lahham; Franz-Josef Schmitz
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

8.  Detection of multiple macrolide- and lincosamide-resistant strains of Streptococcus pyogenes from patients in the Boston area.

Authors:  Meredith E Hasenbein; John E Warner; Kathleen G Lambert; Sarah E Cole; Andrew B Onderdonk; Alexander J McAdam
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

9.  High prevalence of the ermB gene among erythromycin-resistant streptococcus pneumoniae isolates in Germany during the winter of 2000-2001 and in vitro activity of telithromycin.

Authors:  Michael Kresken; Beate Henrichfreise; Simone Bagel; Johannes Brauers; Bernd Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

10.  In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.

Authors:  Tsuyoshi Otani; Mayumi Tanaka; Emi Ito; Yuichi Kurosaka; Yoichi Murakami; Kiyomi Onodera; Takaaki Akasaka; Kenichi Sato
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.